Drug intelligence / Profile preview

measles, mumps and rubella combined vaccine, live

Development stage: Phase 4
Lead developer: Shanghai Institute of Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

Measles, mumps and rubella combined vaccine, live, also known as MMR, is a live-attenuated combination vaccine designed to provide active immunity against measles, mumps, and rubella viral infections. It contains weakened forms of the measles, mumps, and rubella viruses, which stimulate the immune system to produce antibodies and create immunological memory, thereby offering long-term protection without causing the diseases themselves. The vaccine is indicated for active immunization for the prevention of these three diseases. Shanghai Institute Of Biological Products is involved in its development and evaluation.

Other names: MMR

Beyond the preview

Go deeper on measles, mumps and rubella combined vaccine, live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles, mumps and rubella combined vaccine, live.

Explore the full profile